Hepatobiliary system cancer
Conditions
Interventions
Sponsors
Tianjin Third Central Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: ? between 40 and 75 years old; ? Primary liver cancer or cholangiocarcinoma that meets the clinical diagnostic criteria of NCCN Guidelines Version 2.202 or is confirmed by histopathology or cytology; (3) Meet the indication of radical resection (restricted to open surgery); ? Child-Pugh liver function grade A or B; ? ECOG-PS score 0-1; ? Expected survival =6 months; ? Subjects voluntarily participate and sign informed consent.
Exclusion criteria
Exclusion criteria: Patients with any of the following conditions are not allowed to enter or continue the study: ? Have a history of immunosuppressive drugs or a history of immune deficiency; ? Have seen other clinical experimenters in the last three months; ? Patients with previous malignant tumors <5 years; ? Patients who have received other surgical treatment for less than 6 months; (5) Women who are breastfeeding, pregnant or planning to become pregnant; ? Patients who are known to be allergic to test sample components or their analogues; 7 Patients with contraindications to abdominal perfusion; 8 Patients with cognitive impairment or poor treatment compliance determined by researchers; Other severe, acute, or chronic medical conditions that may interfere with the findings; ? Other conditions deemed unsuitable for inclusion or inappropriate for clinical trials by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immune cell subsets; | — |
Secondary
| Measure | Time frame |
|---|---|
| Average length of stay;Postoperative complication; | — |
Countries
China
Contacts
Public ContactWang Ximo
Tianjin Third Central Hospital
Outcome results
None listed